Metabolomics in Toxicology and Preclinical Research
The Chemical Company BASF SE and the Centre of Alternatives to Animal Testing – Europe (CAATEurope) is inviting to the Symposium on ‘Metabolomics in Toxicology and Preclinical Research’, held on Monday February 13th 2012 in Berlin, Germany. The Symposium will focus on the state-of-the-art und potential applications of metabolomics in toxicology and preclinical research.
- Improve our understanding about the toxicological profile of a given compound; i.e. identifying its toxicological mode of action(s),
- Identifying biomarkers that can potentially be used to identify pathophysiological conditions or in cases of drugs used for treatment monitor efficacy of treatment and
- Identify biochemical pathway changes following exposure.
The metabolomics technology is particularly suitable to be applied using body fluid matrices, such as urine and blood, enabling comprehensive insights into metabolic responses to e.g. chemical exposure without analyzing individual organs. In toxicology the first applications have been for mechanistic research and early identification of toxicological effects. Recognition and understanding the cause of (patho)toxicological effects based on identification of mode of action(s) will greatly enhance the quality of toxicological studies and aid the risk assessment process. Moreover, overall comparisons of metabolome profiles of chemicals should provide comprehensive biological information which will enable us to build better chemical categories for safety assessment. Finally, based on the successful application of metabolomics in chemically induced toxicity, it should be feasible to use this technology for the identification of diseases.
This Symposium brings together scientists from academia, industry and regulatory bodies to present the current status of this technology and its applicability in toxicology, particularly for safety assessment of compounds.